

June 30, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated June 30, 2018 titled "Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Tablets USP."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

for,

UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above



Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Tablets USP

Ahmedabad, 30 June, 2018

Zydus Cadila has received the final approval from the USFDA to market Triamterene and Hydrochlorothiazide Tablets USP in strengths of 37.5 mg/25 mg and 75 mg/50 mg. It is used for the treatment of high blood pressure. This combination drug is used by patients who have developed or are at risk for having low potassium levels on hydrochlorothiazide. It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has more than 195 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
